Background
Methods
Patient population
Device interrogation and programming
CMR imaging protocol
CMR image quality
CMR–based change in diagnosis or treatment
Statistical analysis
Results
Patient characteristics
All patients (n = 208) | Primary prevention (n = 115) | Secondary prevention (n = 93) | p–value | |
---|---|---|---|---|
Age, years | 60 ± 12 | 60 ± 11 | 59 ± 13 | 0.532 |
Gender, male, n(%) | 174 (84) | 98 (85) | 76 (82) | 0.498 |
BMI, kg/m2 | 28.6 ± 5.1 | 29.2 ± 5.3 | 27.9 ± 4.8 | 0.062 |
Hypertension, n(%) | 144 (69) | 80 (70) | 64 (69) | 0.907 |
Diabetes, n(%) | 46 (22) | 32 (28) | 14 (15) | 0.027 |
CHA2DS2–VASc Score | 2.7 ± 1.4 | 2.8 ± 1.2 | 2.4 ± 1.5 | 0.006 |
NYHA class | 1.9 ± 0.9 | 2.1 ± 0.9 | 1.6 ± 1.0 | 0.001 |
Known CAD, n(%) | 83 (40) | 52 (45) | 31 (33) | 0.082 |
Severity of CAD | 0.178 | |||
Single–vessel, n(%) | 31 (37) | 18 (35) | 13 (42) | |
Multi–vessel, n(%) | 52 (63) | 34 (65) | 18 (58) | |
Electrical instability | 0.009 | |||
≤ 2 adequate ATP/shock(s), n(%) | 23 (11) | 16 (14) | 7 (8) | |
Electrical storm, n(%) | 107 (51) | 53 (46) | 54 (58) | |
Below detection, n(%) | 11 (5) | 3 (3) | 8 (9) | |
Inadequate ATP/shock(s), n(%) | 15 (7) | 6 (5) | 9 (10) | |
Prior VT ablation, n(%) | 50 (24) | 16 (14) | 34 (37) | < 0.001 |
Antiarrhythmic drugs | ||||
Betablockers, n(%) | 189 (91) | 104 (90) | 85 (91) | 0.811 |
Class I, n(%) | 14 (7) | 5 (4) | 9 (10) | 0.127 |
Class III, n(%) | 60 (29) | 31 (27) | 29 (31) | 0.504 |
Device characteristics | 0.070 | |||
S–ICD, n(%) | 6 (3) | 5 (4) | 1 (1) | |
Single chamber ICD, n(%) | 101 (49) | 55 (48) | 46 (49) | |
Dual chamber ICD, n(%) | 65 (31) | 30 (26) | 35 (38) | |
CRT–D, n(%) | 36 (17) | 25 (22) | 11 (12) | |
MR-conditional devices, n(%) | 94 (45) | 48 (42) | 46 (49) | 0.266 |
Time since ICD implantation, months | 58.9 ± 50.0 | 56.4 ± 42.4 | 61.9 ± 58.2 | 0.436 |
Range, months | 1.4–240.4 | 1.6–225.0 | 1.4–240.4 |
CMR imaging protocol
All patients (n = 208) | Primary prevention (n = 115) | Secondary prevention (n = 93) | p–value | |
---|---|---|---|---|
Heart rate, bpm | 68 ± 14 | 70 ± 14 | 64 ± 13 | 0.002 |
Systolic BP, mmHg | 127 ± 20 | 124 ± 20 | 130 ± 21 | 0.010 |
Diastolic BP, mmHg | 73 ± 12 | 73 ± 12 | 74 ± 12 | 0.888 |
LVEDV, ml | 249 ± 106 | 283 ± 111 | 207 ± 83 | < 0.001 |
LVESV, ml | 170 ± 102 | 207 ± 104 | 125 ± 78 | < 0.001 |
LVEF, % | 36 ± 15 | 30 ± 13 | 44 ± 13 | < 0.001 |
RVEDV, ml | 128 ± 65 | 133 ± 71 | 121 ± 55 | 0.163 |
RVESV, ml | 62 ± 48 | 66 ± 53 | 57 ± 40 | 0.139 |
RVEF, % | 54 ± 11 | 54 ± 12 | 56 ± 10 | 0.186 |
LGE positive (n = 206), n(%) | 135 (66) | 73 (65) | 62 (67) | 0.756 |
LV, LGE positive, n(%) | 132 (64) | 73 (65) | 59 (63) | 0.863 |
LV-LGE pattern (n = 132) | 0.862 | |||
subendocardial, n(%) | 82 (62) | 47 (64) | 35 (59) | |
subepicardial, n(%) | 14 (11) | 7 (10) | 7 (12) | |
midwall striae, n(%) | 23 (17) | 13 (18) | 10 (17) | |
midwall patchy, n(%) | 13 (10) | 6 (8) | 7 (12) | |
LV-LGE, segments | 4.1 ± 2.7 | 4.2 ± 2.8 | 4.0 ± 2.5 | 0.647 |
LV-LGE, % transmurality | 73 ± 25 | 75 ± 24 | 70 ± 26 | 0.243 |
RV, LGE positive, n(%) | 9 (4) | 2 (2) | 7 (8) | 0.044 |
LV thrombus, n(%) | 9 (4) | 5 (4) | 4 (4) | 0.987 |
CMR image quality
CMR–based change in diagnosis
Post-CMR diagnosis | All patients (n = 208) | All patients Change in diagnosis | Primary prevention (n = 115) | Primary prevention Change in diagnosis | Secondary prevention (n = 93) | Secondary prevention Change in diagnosis |
---|---|---|---|---|---|---|
Acute MI | 2 | 2 (1) | 1 | 1 (1) | 1 | 1 (1) |
Cardiac storage disease | 1 | 0 (0) | 1 | 0 (0) | 0 | 0 (0) |
ARVC | 5 | 3 (1) | 1 | 0 (0) | 4 | 3 (3) |
Idiopathic DCM | 43 | 13 (6) | 33 | 9 (8) | 10 | 4 (4) |
HCM | 7 | 2 (1) | 3 | 1 (1) | 4 | 1 (1) |
HHD | 25 | 22 (11) | 11 | 11 (10) | 14 | 11 (12) |
ICM | 63 | 8 (4) | 40 | 2 (2) | 23 | 6 (6) |
NCCM | 1 | 1 (0.5) | 0 | 0 (0) | 1 | 1 (1) |
Normal (prior LGE (+) VT ablation lesions) | 4 | 4 (2) | 1 | 1 (1) | 3 | 3 (3) |
Normal | 21 | 10 (5) | 5 | 4 (3) | 16 | 6 (6) |
Post–acute myocarditis | 20 | 13 (6) | 9 | 5 (4) | 11 | 8 (9) |
PPCM | 2 | 0 (0) | 2 | 0 (0) | 0 | 0 (0) |
Cardiac sarcoidosis | 7 | 4 (2) | 4 | 2 (2) | 3 | 2 (2) |
Systemic sclerosis | 1 | 0 (0) | 0 | 0 (0) | 1 | 0 (0) |
TOF | 1 | 0 (0) | 0 | 0 (0) | 1 | 0 (0) |
VHD | 5 | 1 (0.5) | 4 | 1 (1) | 1 | 0 (0) |
Total | 208 | 83 (40) | 115 | 37 (32) | 93 | 46 (49)* |
CMR–based change in treatment
Post-CMR Treatment | All patients (n = 208) | All patients Change in treatment | Primary prevention (n = 115) | Primary prevention Change in treatment | Secondary prevention (n = 93) | Secondary prevention Change in treatment |
---|---|---|---|---|---|---|
Coronary Revasc | 10 | 10 (5) | 5 | 5 (4) | 5 | 5 (5) |
CRT upgrade | 3 | 3 (1) | 2 | 2 (2) | 1 | 1 (1) |
LVAD | 2 | 1 (0.5) | 2 | 1 (1) | 0 | 0 (0) |
Medical therapy | 56 | 27 (13) | 32 | 15 (13) | 24 | 12 (13) |
PVI | 13 | 1 (0.5) | 8 | 1 (1) | 5 | 0 (0) |
PV angioplasty | 1 | 1 (0.5) | 1 | 1 (1) | 0 | 0 (0) |
VT ablation | 123 | 0 (0) | 65 | 0 (0) | 58 | 0 (0) |
Total | 208 | 43 (21) | 115 | 25 (22) | 93 | 18 (19)* |